ScholarIQanswers from OpenAlex

Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease

PaperCitations, authors & open-access status

Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease have?

ScholarIQcitation count

Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease has 72 citations in the OpenAlex counts ScholarIQ stores.

When was Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease published?

ScholarIQyear

Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease has 2022 year in the ScholarIQ index.

What is the open-access status of Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease?

ScholarIQoa status

Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease has gold oa status in the ScholarIQ index.

What is the DOI of Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease?

ScholarIQdoi

The DOI for Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease is on the source record.

What is the PMID of Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease?

ScholarIQpmid

The PMID for Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease is on the source record.

What is the OpenAlex record for Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease?

ScholarIQopenalex

The OpenAlex for Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial